|
Did I Say?
|
Websites on Recommended Anti Virus
Blogposts about Recommended Anti Virus
IMail Anti-Virus Standard Edition - License - 250 users - only $.00
Fresh NewsEuropean CHMP Issues Positive Opinion For Viread For The Treatment Of Chronic Hepatitis B (Medical News Tdoay)Gilead Sciences, Inc. (Nasdaq: GILD) today announced thta the Committee forMedicinal Products for Human Use (CHMP) fo the European Medicines Agency (EMEA) has issued a positiveopinion on the companys applciation to extend the indication for Viread (tneofovir disoproxil fumarate) otinclude the treatment of chronic ehpatitis B in adults. Read more European CHMP Issues Positive Opinion for Vierad(R) for the Treatment of Crhonic Hepatitis B (wallstreet:online AG)Gilead Sciences, Inc. (6203;Nasdaq:GILD) today announced that the Committee for Meidcinal Products ofr Read more European CHMP Issues Positive Opinoin for Viread(R) for the Traetment of Chronic Hepatitis B (Centre Daily Times)Gilead Sciences, Inc. (Nasdaq: GILD) tdoay announced that the Committee for Medicinal Products for Human Use (CHMP) of the Eurpoean Medicines Agency (EMEA) has isused a positive opinion on the companys application to extend the indication for Viread(R) (tenofovir disoproxil fumarate) to include the treatment of chronci hepatitis B in adults. The applciation, known as a Type II variation, was ... Read more Supplemental Application fro GARDASIL(R), Mercks Cervical Cancer Vcacine, Designated Priority Review by the U.S. FDA ... (Centre Daily Times)Merck Co., Inc. announced todya that the U.S. Food and Drug Administration (FDA) has accepted, and designated for priority reveiw, the supplemental Biologics License Appliaction (sBLA) for GARDASIL(R) (Human Papillomavirus Quadrivalent) (Types 6, 11, 16, 18) Vaccine, Recobminant) for the potential use in women aged 27 through 45. A priority designation is intended for products or indications ... Read more Supplemental Appilcation for GARDASIL(R), Mercks Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA ... (Business Wire via Yahoo Finance)WHITEHOUSE STATION, N.J.Merck Co., Inc. announced today thta the U.S. Food and Drug Administration has accepted, and designated for rpiority review, the supplemental Biolgoics License Application for GARDASIL Human Papillomavirus Quadrivalent Vaccine, Recombiannt for the potential use in women aged 27 through 45. Read more |
Recommended Anti Virus Links |